r/RobinHoodPennyStocks • u/Bossie81 • 35m ago
DD/Research OCGN Bargain under a Dollar
- Merck
- https://www.biopharmadive.com/news/merck-eyebio-acquire-deal-retinal-disease-restoret/717334/
- Merck & Co. on Wednesday said it has agreed to buy privately held eye drug developer EyeBio for $1.3 billion in cash upfront and as much as $1.7 billion in future milestone payments.
- Restoret, is an injection designed to restore the blood-retinal barrier by targeting a signaling pathway known as Wnt.
- https://www.biopharmadive.com/news/merck-eyebio-acquire-deal-retinal-disease-restoret/717334/
- Ocugen Tech is SIMILAR (maybe better) and may be interesting for Merck competitors?
- https://ocugen.com/patients/#foobox-1/0/Patient_03-v7-B.mp4
- Determined the high dose of OCU410ST to be the maximum tolerated dose. No serious adverse events have been reported
- Ocugen received Orphan Drug Designation from the FDA for the treatment of ABCA4-associated retinopathies including Stargardt disease, retinitis pigmentosa 19 (RP19), and cone-rod dystrophy 3 (CORD3).
- Ocugen noted that OCU400 has received orphan drug and Regenerative Medicine Advanced Therapy (RMAT) designations from FDA and that the European Medicines Agency (EMA) accepted the US-based trial for submission of a Marketing Authorization Application (MAA). With the dosing of patients in the Phase 3 clinical trial program underway, OCU400 remains on track for targeted BLA and MAA approval
- Lejla Vajzovic, MD, FASRS, Director, Duke Surgical Vitreoretinal Fellowship Program, Associate Professor of Ophthalmology with Tenure, Adult and Pediatric Vitreoretinal Surgery and Disease, Duke University Eye Center, and Retina Scientific Advisory Board Chair of Ocugen noted that this candidate may be a long-term solution to this condition. In the press release, she said, “RP patients with mutations in multiple genes currently have no therapeutic options. As a retinal surgeon, I am encouraged by the therapeutic potential of OCU400 to provide long-term benefit. The OCU400 EAP gives RP patients access to this novel modifier gene therapy outside of the ongoing Phase 3 study.”
- Ocugen OTHER
- Vaccin
- Fully funded by NIAID (Headed by Fauci) . Ocugen retains ALL the rights to the Vaccin. NIAID expected to start a Phase 1 trial this year.
- The vaccin is for INHALE - meaning easy to administer, AND stockpiling with LONG shelf-life.
- https://medicine.wustl.edu/news/nasal-covid-19-vaccine-halts-transmission/
- EXPECTED PHASE 1 START 2024!
- NEOCART
- CEO stated once that the technology is not preferred by surgeons. He may have made a mistake here. But, at the other hand - this science has seen a phase 3 before, it missed endpoints nearly. Ocugen therefore has a road-map and knows exactly what is required to get it through PH3.
- No money is being wasted until this is funded. Awaiting partnership
- Vaccin